European Commission President Ursula von der Leyen, speaking at the Conference 'Advancing Brain Cancer Research: From policy action to scientific breakthroughs' on World Brain Tumour Day, 8 June 2026, pledged continued EU commitment to fighting cancer, with a focus on prevention, faster treatment development, equal access, and support for survivors. She noted that around 42,000 people in the EU are diagnosed with brain tumours annually and 36,000 die, and stressed the need to turn hope into reality through research and policy.
Von der Leyen outlined four priorities: boosting prevention, which could avert 40% of cases; accelerating clinical trial approvals via the European Biotech Act and improving data-sharing through the European Health Data Space; tackling inequalities in early detection and treatment; and strengthening support for survivors, including the right to be forgotten in insurance and loans. She recalled personal experiences with cancer in her family and as a medical student to underscore the urgency.
The speech did not announce new funding or legislative proposals beyond existing initiatives. It reiterated commitments under Europe's Beating Cancer Plan, which invests EUR 4 billion overall, including EUR 600 million for research. Von der Leyen also highlighted progress on HPV vaccination, with some Member States reaching 90% coverage of young girls, leading to reduced cervical cancer rates.
Stakeholder impacts: Patients and survivors stand to benefit from improved access to care and data-driven treatments, but implementation depends on Member State action. The biotech industry may see streamlined clinical trial approvals, reducing costs and time to market. National health systems face pressure to equalise screening and treatment access, potentially increasing public spending. Insurers could be affected by the right to be forgotten, limiting their ability to adjust premiums based on cancer history.
Importance score: 65 – a high-level policy speech reaffirming existing commitments without new concrete measures, of moderate interest to EU health policy watchers and cancer research communities.